Calendario›SNY›trivalent · VXB251-001

trivalent · VXB251-001

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

Ensayo de Sanofi en Lower Respiratory Tract Disease · Healthy Participants (del registro, en inglés).

Fase

Fase 1

Estado

En marcha, sin reclutar

Participantes

240

previstos

Centros

6

Fin del objetivo primario

abr 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en nov 2025.

Qué mide

Proportion of Participants With 1 or More Unsolicited Adverse Events (AEs) (1 month after IMP injection) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is being done to find out how safe and effective a new combined vaccine candidate, called VXB-251, is for older adults. The vaccine candidate is designed to protect against three common viruses that can cause respiratory tract infections: * RSV (respiratory syncytial virus) * hMPV (human metapneumovirus) * PIV3 (parainfluenza virus type 3) Two components of this vaccine (RSV and hMPV) have already been tested in people before, as part of another study for a two-in-one vaccine. However, this is the first time that the PIV3 component and all three components together (RSV, hMPV, and PIV3) are being tested in people. The vaccine candidate will be given as a single intramuscular injection. The study will also test unlicensed comparator vaccines and a placebo (a substance that looks like the real vaccine but doesn't contain any active ingredients) that target none, one or two of these viruses to see whether combining all three components affects safety or how well the immune system responds.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07295028), actualizada en may 2026.